<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB2852</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB2852 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB2852</pre></b></center><p> </p>Introduced 2/6/2025, by Rep. Janet Yang Rohr<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>20 ILCS 2310/2310-735 new</code></td><td class="synopsis"></td></tr><tr><td class="synopsis"><code>215 ILCS 5/370c.3 new</code></td><td class="synopsis"></td></tr><tr><td class="synopsis"><code>305 ILCS 5/5-58 new</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Creates the Nonopioid Alternatives for Pain Act. Allows the </code><code>Department of Public Health to develop and publish on its website a </code><code>nonopioid alternatives pamphlet, with certain requirements. Prohibits a </code><code>health insurance issuer to deny coverage of a nonopioid prescription drug </code><code>in favor of an opioid prescription drug. Amends the Illinois Public Aid </code><code>Code. Provides that coverage shall not be denied for a nonopioid </code><code>prescription drug in favor of an opioid prescription drug. Requires that </code><code>nonopioid drugs preferred on a specific list for the treatment or </code><code>management of pain shall not be disadvantaged or discouraged with respect </code><code>to coverage relative to any opioid or narcotic drug for the treatment or </code><code>management of pain. Effective July 1, 2027.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 09629 BDA 19694 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2852</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 09629 BDA 19694 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning health.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>The Department of Public Health Powers and </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Duties Law of the Civil Administrative Code of Illinois is </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>amended by adding Section 2310-735 as follows:</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(20 ILCS 2310/2310-735 new)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 2310-735. </code></u><u><code>Nonopioid alternatives pamphlet. </code></u><u><code>The </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>Department of Public Health may develop and publish on its </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>website an educational pamphlet regarding the use of nonopioid </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>alternatives for the treatment of acute nonoperative, acute </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>perioperative, subacute, or chronic pain. The pamphlet may </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>conform with the United States Department of Health and Human </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>Services' Pain Management Best Practices Inter-Agency Task </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>Force recommendations and shall include:</code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(1) information on available nonopioid alternatives </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <u><code>for the treatment of pain, including available nonopioid </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <u><code>medicinal drugs or drug products and nonpharmacological </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <u><code>therapies; and</code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(2) the advantages and disadvantages of the use of </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <u><code>nonopioid alternatives.</code></u><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 10. </code><code>The Illinois Insurance Code is amended by </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2852</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 09629 BDA 19694 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>adding Sections 370c.3 as follows:</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(215 ILCS 5/370c.3 new)</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 370c.3. </code></u><u><code>Coverage for nonopioid medications; pain </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><u><code>relief parity.</code></u><code> </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(a) In this Section, "health insurance issuer" has the </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><u><code>meaning set forth in Section 5 of the Illinois Health </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><u><code>Insurance Portability and Accountability Act.</code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(b) Notwithstanding any provision of law to the contrary, </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>when a licensed health care practitioner prescribes a </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>nonopioid medication for the treatment of acute pain, it shall </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>be unlawful for a health insurance issuer to deny coverage of </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>the nonopioid prescription drug in favor of an opioid </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>prescription drug or to require the patient to try an opioid </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>prescription drug prior to providing coverage of the nonopioid </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>prescription drug.</code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(c) In establishing and maintaining its drug formulary, a </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><u><code>health insurance issuer shall ensure that no nonopioid drug </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><u><code>approved by the United States Food and Drug Administration for </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><u><code>the treatment or management of pain shall be disadvantaged or </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><u><code>discouraged, with respect to coverage or cost sharing, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><u><code>relative to any opioid or narcotic drug for the treatment or </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><u><code>management of pain on the health insurance issuer's drug </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><u><code>formulary, where impermissible disadvantaging or </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><u><code>discouragement includes, without limitation: imposing more </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><u><code>restrictive coverage criteria on any such nonopioid drug than </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2852</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 09629 BDA 19694 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><u><code>the least restrictive coverage criteria imposed on an opioid </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><u><code>or narcotic drug; establishing more restrictive or more </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><u><code>extensive utilization controls, including, but not limited to, </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><u><code>more restrictive or more extensive prior authorization or step </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><u><code>therapy requirements, for such nonopioid drug than the least </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><u><code>restrictive or extensive utilization controls applicable to </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><u><code>any such opioid or narcotic drug; or, if the health insurance </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><u><code>issuer maintains a drug formulary grouped into tiers for the </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>purposes of determining cost sharing, placing any such </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>nonopioid drug on a tier that requires a cost-sharing </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>responsibility that exceeds the lowest cost-sharing </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>responsibility required for any opioid or narcotic drug on the </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>drug formulary. This subsection does not preclude opioid drugs </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>from being preferred over other opioid drugs or nonopioid </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>drugs from being preferred over other nonopioid drugs.</code></u><br> </td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 15. </code><code>The Illinois Public Aid Code is amended by </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>adding Section 5-58 as follows:</code><br> </td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(305 ILCS 5/5-58 new)</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 5-58. </code></u><u><code>Coverage for nonopioid medications; pain relief </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><u><code>parity.</code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(a) Required coverage for nonopioid medications. </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><u><code>Notwithstanding any provision of law to the contrary, whenever </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><u><code>a licensed health care practitioner prescribes a nonopioid </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><u><code>medication for the treatment of acute pain, neither the </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB2852</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 09629 BDA 19694 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><u><code>Department nor a managed care organization contracted with the </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><u><code>Department shall deny coverage of the nonopioid prescription </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><u><code>drug in favor of an opioid prescription drug or require a </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><u><code>patient to try an opioid prescription drug prior to providing </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><u><code>coverage of the nonopioid prescription drug.</code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(b) Pain relief parity. In establishing and maintaining </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><u><code>the Illinois Medicaid Preferred Drug List, the Department </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><u><code>shall ensure that nonopioid drugs preferred on the </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>Department's preferred drug list, and approved by the U.S. </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>Food and Drug Administration, for the treatment or management </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>of pain shall not be disadvantaged or discouraged with respect </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>to coverage relative to any opioid or narcotic drug for the </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>treatment or management of pain.</code></u><br> </td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 99. </code><code>Effective date. </code><code>This Act takes effect January </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>1, 2027.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
